Real World Data Europe 2013 to prove and improve health outcomes

Share Article

"From the dawn of civilization to 2003, five exabytes of data were created. The same amount was created in the last two days," Eric Schmidt, CEO, Google

News Image
“Big data” has become a topic of debate, excitement and tantalising promise for marketeers the world over – the possibilities to learn about your customer are endless.

People have access to more information than at any other point in history, and the wealth of data at their fingertips means that today’s landscape is very different to the one we faced in 2003. “Big data” has become a topic of debate, excitement and tantalising promise for marketeers the world over – the possibilities to learn about your customer are endless.

The implications for healthcare are even greater. With the patient data that is available, there is the opportunity to change healthcare and healthcare delivery. The possibility to improve health outcomes for patients and payers alike. The ability to deliver a stronger market proposition and vastly improve success in value-based reimbursement.

But despite this potential, there are still many unanswered questions:

Who wants this data? Who pays for it? What are the legislative hurdles? How to collect this data and in turn how to use the data that has been collected? Most importantly of all, how to prepare for this information revolution? What are the necessary steps that must be taken?

At Real World Data Europe, payers and HTA agencies from across Europe will answer the hard questions on Real World Evidence. Learn from the G-BA why real world data requirements in Germany differ to the rest of Europe. Understand how NICE’s value based pricing will make real world data an absolute must for pharma companies. Learn how payers in France have made innovative partnerships to meet post-reimbursement agreements. Here how pharma across Europe have been making sense of real world data.

It’s a program made for pharma, payers & HTA agencies and made by pharma, payers & HTA agencies. It’s independently research with over 35 speakers from across Europe. NICE, NHS, G-BA, AETS, EUnetHTA join, EFPIA, AstraZeneca, Amgen, Novartis and more to define the future of healthcare.

Key topics include:

New partnerships: Create win-win partnerships with payers, data sources and IT companies to fill unmet payer requirements through real case studies

New data sources: Learn how EHR, PROs, PROMs, EPDs, social media and new sources of patient data can be generated and found to keep ahead of the competitors

New uses: Proven methods of how data can be used to improve service delivery and cut drug development costs & how real life data has changed the dynamics of reimbursement, clinical trial design and product strategy

New stakeholder environment: Understand new payer, regulator and HTA agency attitudes to real world data to save money, time and resources in your evidence generation

New initiatives: Learn what EFPIA, the European Commission, the UK and the US have been doing to make the most of real world data.

For the complete Real World Data Europe 2013 conference programme and speaker line-up, access the e-brochure at http://bit.ly/10nVIQo or contact Lanre at lanre(at)eyeforpharma(dot)com

Register today to join the people that shape European healthcare. Book before March 8th and save €600: http://bit.ly/XUgCH2

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lanre Ibitoye
eyeforpharma
+44 207 375 7592
Email >
Follow us on
Visit website